Ivanova K.


About the author:

Ivanova K.



Type of article:

Scentific article


Cardiovascular diseases are the main cause of disability and premature mortality worldwide, which necessitates a detailed study of the risk factors for cardiovascular disorder. Overweight and obesity are the most important factors that reduce the sensitivity of tissues to insulin. According to modern ideas, fatty tissue is a place for the synthesis of many adipocytokines, among which the fibroblast growth factor 21 (FRF21). The fibroblast growth factor 21 (FRF21) is a hormone-like cytokine recognized as a potent metabolic regulator. Previous studies have established lipid-lowering, anti-inflammatory and antioxidant properties of FRF21. Serum levels of FRF21 were also higher in obese patients and type 2 diabetes mellitus (DM2T), so FRF21 was suggested as a predictor of metabolic syndrome and DM2T. The aim of the study was to study the relationship between the serum fibroblast growth factor level 21 and insulin resistance syndrome in patients with coronary artery disease (CAD), depending on the presence and extent of obesity, as well as establishing an association with anthropometric indicators. Object and methods. 98 patients with CAD who were divided into 4 groups depending on the body mass index were examined. The control group consisted of 20 healthy people, corresponding to sex and age. The patients were examined according to a standard protocol. In addition, the level of FRF 21 and fasting serum insulin was determined by ELISA using the ELISA Kit AVISCERA BIOSCIENCE SK00145-01 (USA) and DRG® Insulin (DRG Instruments gmbh, Germany, Marburg) with the enzyme immunoassay. Results and discussion: the adherence of obesity in patients with IHD with an unfavorable factor in the formation of insulin resistance or type 2 diabetes. This assumption is the result of studies that determine the protective role of this cytokine in the development of changes in carbohydrate metabolism. Conclusions. The level of FRF21 is related to the degree of obesity, as well as the state of the carbohydrate profile.


fibroblast growth factor 21, insulin resistance, carbohydrate profile, coronary heart disease, obesity


  1. Kharitonenkov A, Shiyanova TL, Koester А, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005;115:1627-35.
  2. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, et al. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 2006;55:2470-8. DOI: 10.2337/db05-1435
  3. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5:415-25. DOI: 10.1016/j.cmet.2008.05.006
  4. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 2009;150:4625-33. DOI: 10.1210/en.2009-0119
  5. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010 Nov;59(11):2781-9. DOI: 10.2337/db10-0193
  6. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat. Commun. 2013;4:2019.
  7. Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 2013;19:1147-52. DOI: 10.1038/nm.3249
  8. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008;149:6018-27. DOI: 10.1210/en.2008-0816
  9. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol. Med. 2011;17:736-40. DOI: 10.2119/molmed.2011.00075
  10. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, De Fronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32:1542-6. DOI: 10.2337/dc09-0684
  11. Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Mohlig M, Mai K, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care. 2013;36:145-9. DOI: 10.2337/dc12-0703
  12. Chu AY, Workalemahu T, Paynter NP, Rose LM, Giulianini F, Tanaka T, et al. Novel locus including FGF21 is associated with dietary macronutrient intake. Hum. Mol. Genet. 2013;22:1895-902.
  13. Lin Z, Pan X, Wu F, Ye D, Zhang Y, Wang Y, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation. 2015;131(21):1861-71. DOI: 10.1161/circulationaha.115.015308
  14. Stabil’naya ishemicheskaya bolezn’ serdca: adaptirovana klinicheskaya ustanovka, osnovannaya na dokazah. K.: 2016. 177 s. [in Russiаn].
  15. Unificirovannyj klinicheskij protokol pervichnoj i vtorichnoj (specializirovannoj) medicinskoj pomoshchi: Stabil’naya ishemicheskaya bolezn’ serdca. Prikaz MZ Ukrainy ot 02.03.2016 № 152. 61 s. [in Russiаn].
  16. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010 Nov;59(11):2781-9. DOI: 10.2337/db10-0193
  17. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia. 2011 Dec;54(12):3093-100. DOI: 10.1007/s00125-011-2317-z
  18. Li X, Fan X, Ren F, Zhang Y, Shen C, Ren G, et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diabetes Res Clin Pract. 2011 Jul;93(1):10-6. PMID: 21596453. DOI: 10.1016/j. diabres.2011.02.034
  19. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010 Oct;40(10):887-92. PMID: 20624171. DOI: 10.1111/j.1365-2362.2010.02338.x
  20. Mashili FL, Austin RL, Deshmukh AS, Fritz T, Caidahl K, Bergdahl K, et al. Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. Diabetes Metab. Res. Rev. 2011;27:286-97. DOI: 10.1002/dmrr.1177

Publication of the article:

«Bulletin of problems biology and medicine» Issue 3 (145), 2018 year, 108-112 pages, index UDK 616.127-005.4-056.257-078:[577.175.72:577.112].088.6:577.121